Longistatin, a novel plasminogen activator from vector ticks, is resistant to plasminogen activator inhibitor-1

Biochemical and Biophysical Research Communications

Volumn 413, Issue 4, 2011, Pages 599-604

  Anisuzzaman, ^a,b   Khyrul Islam, M ^b,c   Abdul Alim, M ^b   Miyoshi, Takeharu ^b   Hatta, Takeshi ^b   Yamaji, Kayoko ^b   Matsumoto, Yasunobu ^a   Fujisaki, Kozo ^d   Tsuji, Naotoshi ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b NATIONAL INSTITUTE OF ANIMAL HEALTH   (Japan)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Fibrinolysis; Longistatin; Plasminogen activator; Plasminogen activator inhibitor 1; Tick

Indexed keywords

FIBRINOLYTIC AGENT; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT LONGISTATIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE;

ARTICLE; BLOOD CLOT LYSIS; CELL LYSATE; COMPLEX FORMATION; FIBRINOLYSIS; HAEMAPHYSALIS LONGICORNIS; HUMAN; NONHUMAN; PLASMINOGEN ACTIVATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; THROMBOCYTE; THROMBOEMBOLISM; TICK;

ANIMALS; CALCIUM-BINDING PROTEINS; CELLS, CULTURED; DISEASE VECTORS; FIBRIN; HUMANS; IXODES; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATORS; SALIVARY PROTEINS AND PEPTIDES;

HAEMAPHYSALIS LONGICORNIS; IXODIDA;

EID: 80053584201     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.09.009     Document Type: Article

References (24)

1. Murray V., Norrving B., Sandercock P.A., Terént A., Wardlaw J.M., Wester P. The molecular basis of thrombolysis and its clinical application in stroke. Journal of Internal Medicine 2010, 267:191-198.
2. Baldwin K., Orr S., Briand M., Piazza C., Veydt A., McCoy S. Acute ischemic stroke update. Pharmacotherapy 2010, 30:493-514.
3. Roger V.L., Go A.S., Lloyd-Jones D.M., et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011, 123:e18-e209.
4. Heidenreich P.A., Trogdon J.G., Khavjou O.A., et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011, 123:933-944.
5. Killer M., Ladurner G., Kunz A.B., Kraus J. Current endovascular treatment of acute stroke and future aspects. Drug Discovery Today 2010, 15:640-647.
6. Zhu Y., Carmeliet P., Fay W.P. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation 1999, 99:3050-3055.
7. Cesarman-Maus G., Hajjar K.A. Molecular mechanisms of fibrinolysis. British Journal Haematology 2005, 129:307-321.
8. Rijken D.C., Lijnen H.R. New insights into the molecular mechanisms of the fibrinolytic system. Journal of Thrombosis and Haemostasis 2009, 7:4-13.
9. Deng G., Curriden S.A., Wang S., Rosenberg S., Loskutoff D.J. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?. Journal of Cell Biology 1996, 134:1563-1571.
10. Dellas C., Loskutoff D.J. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thrombosis and Haemostasis 2005, 93:631-640.
11. Shohet R.V., Spitzer S., Madison E.L., Bassel-Duby R., Gething M.J., Sambrook J.F. Inhibitor-resistant tissue-type plasminogen activator: an improved thrombolytic agent in vitro. Thrombosis and Haemostasis 1994, 71:124-128.
12. Li X.K., Lijnen H.R., Nelles L., Van Hoef B., Stassen J.M., Collen D. Biochemical and biologic properties of rt-PA del (K296-G302) a recombinant human tissue-type plasminogen activator deletion mutant resistant to plasminogen activator inhibitor-1. Blood 1992, 79:417-429.
13. Hoogstraal H., Roberts F.H., Kohls G.M., Tipton V.J. Review of Haemaphysalis (Kaiseriana) longicornis Neumann (resurrected) of Australia, New Zealand, New Caledonia, Fiji, Japan, Korea, and northeastern China and USSR, and its parthogenetic and bisexual populations (Ixodoidea, Ixodidae.). Journal of Parasitology 1968, 54:1197-1213.
14. Fujisaki K., Kawazu S., Kamio T. The taxonomy of the bovine Theileria spp. Parasitology Today 1994, 10:31-33.
15. Anisuzzaman M., Islam M.K., Alim M.A., et al. Longistatin, a novel EF-hand protein from the ixodid tick Haemaphysalis longicornis, is required for acquisition of host blood-meals. International Journal for Parasitology 2010, 40:721-729.
16. Anisuzzaman M., Islam M.K., Alim M.A., et al. Longistatin, a plasminogen activator, is key to the availability of blood-meals for ixodid ticks. PLoS Pathogens 2011, 7:e1001312.
17. Mimuro J., Schleef R.R., Loskutoff D.J. Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type 1 plasminogen activator inhibitor. Blood 1987, 70:721-728.
18. Islam M.K., Tsuji N., Miyoshi T., et al. The Kunitz-like modulatory protein haemangin is vital for hard tick blood-feeding success. PLoS Pathogens 2009, 5:e1000497.
19. Brogren H., Karlsson L., Andersson M., Wang L., Erlinge D., Jern S. Platelets synthesize large amounts of active plasminogen activator inhibitor 1. Blood 2004, 104:3943-3948.
20. Metha R., Shapiro A.D. Plasminogen activator inhibitor type 1 deficiency. Haemophilia 2008, 14:1255-1260.
21. Davie E.W., Ratnoff O.D. Waterfall sequence for intrinsic blood clotting. Science 1964, 145:1310-1312.
22. Madison E.L., Goldsmith E.J., Gerard R.D., Gething M.J., Sambrook J.F. Serpin-resistant mutants of human tissue-type plasminogen activator. Nature 1989, 339:721-724.
23. Sipley J.D., Alexander D.S., Testa J.E., Quigley J.P. Introduction of an RRHR motif into chicken urokinase-type plasminogen activator (ch-uPA) confers sensitivity to plasminogen activator inhibitor (PAI)-1 and PAI-2 and allows ch-uPA-mediated extracellular matrix degradation to be controlled by PAI-1. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:2933-2938.
24. Le Bonniec B.F., Guinto E.R., Stone S.R. Identification of thrombin residues that modulate its interactions with antithrombin III and alpha 1-antitrypsin. Biochemistry 1995, 34:12241-12248.